It has been reported by Okamoto et al. that CRC tumors with mutant KRAS are able to upregulate BCL-XL via the ERK pathway, which confers resistance to the proteasome inhibitor, Carfilzomib [30]. This evidence concerns the gene KRAS and colorectal carcinoma.